Endologix, Inc. announced that it will present data from its prospective, multicenter clinical trial of the Powerlink Suprarenal Proximal Extension System for the first time at the Society for Clinical Vascular Surgery's (SCVS) 37th Annual Symposium being held in Ft. Lauderdale, Fla. Upon receiving approval from US FDA in October 2008, Endologix is currently marketing the Powerlink Suprarenal Extensions. The principal investigator, Stuart A. Harlin, M.D., FACS, of Sacred Heart Medical Center in Pensacola, Fla. will discuss the data and results in a presentation entitled, "EVAR Using an Anatomical Fixation Technique and Concomitant Suprarenal Orientation: Results of a Prospective, Multicenter Trial." The system is designed with an open cell stent extending above the graft material to allow the physician to position the device at the proximal landing zone without obstructing renal arteries. It is available in multiple diameters and lengths to treat patients with aortic necks up to 32 millimeters in diameter.